Perspective Therapeutics Inc. - Asset Resilience Ratio
Perspective Therapeutics Inc. (CATX) has an Asset Resilience Ratio of 52.82% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Perspective Therapeutics Inc. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Perspective Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See Perspective Therapeutics Inc. (CATX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Perspective Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CATX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $216.96 Million | 52.82% |
| Total Liquid Assets | $216.96 Million | 52.82% |
Asset Resilience Insights
- Very High Liquidity: Perspective Therapeutics Inc. maintains exceptional liquid asset reserves at 52.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Perspective Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Perspective Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 12.10% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Vieworks Co. Ltd
KQ:100120 |
Medical Devices | 7.81% |
|
T&L Co. Ltd
KQ:340570 |
Medical Devices | 26.03% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Perspective Therapeutics Inc. (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Perspective Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 42.74% | $114.11 Million | $266.97 Million | -5.73pp |
| 2024-12-31 | 48.47% | $165.34 Million | $341.10 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $97.89 Million | -- |
| 2023-06-30 | 39.19% | $22.76 Million | $58.09 Million | 0.00pp |
| 2022-12-31 | 39.19% | $22.76 Million | $58.09 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $64.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $64.44 Million | -- |
| 2021-06-30 | 0.00% | $0.00 | $70.42 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $15.51 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $9.42 Million | -- |
| 2018-12-31 | 8.76% | $825.00K | $9.42 Million | -2.31pp |
| 2018-06-30 | 11.07% | $825.00K | $7.46 Million | -13.70pp |
| 2017-12-31 | 24.77% | $3.04 Million | $12.27 Million | 0.00pp |
| 2017-06-30 | 24.77% | $3.04 Million | $12.27 Million | +12.36pp |
| 2016-12-31 | 12.41% | $2.25 Million | $18.10 Million | 0.00pp |
| 2016-06-30 | 12.41% | $2.25 Million | $18.10 Million | -28.29pp |
| 2015-12-31 | 40.70% | $9.36 Million | $23.00 Million | 0.00pp |
| 2015-06-30 | 40.70% | $9.36 Million | $23.00 Million | +3.02pp |
| 2014-12-31 | 37.68% | $10.00 Million | $26.55 Million | 0.00pp |
| 2014-06-30 | 37.68% | $10.00 Million | $26.55 Million | +23.37pp |
| 2009-12-31 | 14.31% | $1.68 Million | $11.74 Million | 0.00pp |
| 2009-06-30 | 14.31% | $1.68 Million | $11.74 Million | -6.61pp |
| 2008-12-31 | 20.92% | $3.73 Million | $17.81 Million | 0.00pp |
| 2008-06-30 | 20.92% | $3.73 Million | $17.81 Million | -17.21pp |
| 2007-12-31 | 38.13% | $9.94 Million | $26.08 Million | 0.00pp |
| 2007-06-30 | 38.13% | $9.94 Million | $26.08 Million | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more